Northside Hospital Research Program

Find Open Clinical Trials

Viewing All Clinical Trials
Showing 1-25 of 102
Protocol ID
Sponsor Protocol ID
Title
Protocol ID:
NSH721
Sponsor Protocol ID:
NMDP IRB-1999-0021
Title:
NMDP Recipient Consent for Participation in Registry, Research Database, and Research Sample Repository [NCT00495300 & NCT01166009]
View Details
Protocol ID:
NSH943
Sponsor Protocol ID:
10-CBA
Title:
A Multicenter Access & Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric & Adult Patients with Hematologic Malignancies & Other Indications
View Details
Protocol ID:
NSH995
Sponsor Protocol ID:
NCBP 6637-01
Title:
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
View Details
Protocol ID:
NSH931
Sponsor Protocol ID:
Title:
Biobank
View Details
Protocol ID:
C-265
Sponsor Protocol ID:
DCP-001
Title:
Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
View Details
Protocol ID:
NSH1158
Sponsor Protocol ID:
Aplastic Anemia
Title:
A Study of T Cell Replete, HLA-Mismatched Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Patients with Severe Aplastic Anemia Lacking HLA- Matched Related Donor
View Details
Protocol ID:
NSH1166
Sponsor Protocol ID:
Title:
CD34 Reagent System Humanitarian Use Device
View Details
Protocol ID:
C-361
Sponsor Protocol ID:
LungMAP
Title:
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
View Details
Protocol ID:
NSH1225
Sponsor Protocol ID:
GC-LTFU-001
Title:
Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T Cells
View Details
Protocol ID:
C-365
Sponsor Protocol ID:
C-365
Title:
Pulmonary Hypertension Association Registry (PHAR) Protocol
View Details
Protocol ID:
C-367
Sponsor Protocol ID:
D9103C00001
Title:
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)
View Details
Protocol ID:
NSH1231
Sponsor Protocol ID:
CCTL019B2003I
Title:
Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or large B-cell lymphoma patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release.
View Details
Protocol ID:
NSH1243
Sponsor Protocol ID:
NSH1243
Title:
An Exploratory Study Evaluating the Effect of Active Barrier on Infection Rate Status Post Hysterectomy
View Details
Protocol ID:
C-389
Sponsor Protocol ID:
S1803
Title:
Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
View Details
Protocol ID:
NSH1249
Sponsor Protocol ID:
NSH1249
Title:
Spiration Valve System Humanitarian Use Device
View Details
Protocol ID:
C-403
Sponsor Protocol ID:
A031704
Title:
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]
View Details
Protocol ID:
NSH1246
Sponsor Protocol ID:
NSH1246
Title:
Phase II trial evaluating the Efficacy and Safety of Sargramostim Post Infusion of T -Replete HLA Mismatched Peripheral Blood Haploidentical Hematopoietic Stem Cells with Post Transplant Cyclophosphamide
View Details
Protocol ID:
C-420
Sponsor Protocol ID:
10323
Title:
Cancer Moonshot Biobank Research Protocol
View Details
Protocol ID:
C-422
Sponsor Protocol ID:
AC-055-315
Title:
A Phase 3, Prospective, Multicenter, Double-blind, Double-dummy, Randomized, Active controlled, Parallel-group, Group-sequential, Adaptive, Event-driven Study to Compare Efficacy, Safety, and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension, Followed by an Open-label Treatment Period With Macitentan 75 mg.
View Details
Protocol ID:
NSH1270
Sponsor Protocol ID:
PBCAR0191-01
Title:
A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR0191 in Subjects with Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
View Details
Protocol ID:
NSH1282
Sponsor Protocol ID:
JCAR017-EAP-001
Title:
Expanded Access Protocol (EAP) for Patients Receiving Lisocabtagene Maraleucel That is Nonconforming for Commercial Release
View Details
Protocol ID:
C-431
Sponsor Protocol ID:
S1827
Title:
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
View Details
Protocol ID:
C-437
Sponsor Protocol ID:
A081801
Title:
Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
View Details
Protocol ID:
C-443
Sponsor Protocol ID:
NRG-CC008
Title:
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROC]
View Details
Protocol ID:
NSH1298
Sponsor Protocol ID:
bb2121-EAP-001
Title:
Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel That is non-conforming for commercial release
View Details
Showing 1-25 of 102

Want to learn more?

For further information on our clinical trials, please call the Northside Hospital Research Program at (404) 303-3355 or

Email Us

For further information on our clinical trials, please contact the Northside Hospital Research Program at
(404) 303-3355 or

Call Us
Email Us